NOV-110101

NOV-110101 is an investigational therapeutic being developed by National OncoVenture for the treatment of pancreatic cancer. It is designed to target Delta-like ligand 1 (DLL1), a transmembrane protein that serves as a ligand for Notch receptors. The Notch signaling pathway is a critical regulator of cell fate, differentiation, and proliferation, and its dysregulation is frequently implicated in the progression of pancreatic ductal adenocarcinoma and the maintenance of cancer stem cells. By binding to DLL1, NOV-110101 is intended to modulate Notch signaling to inhibit tumor growth and overcome therapeutic resistance. The drug is currently in the early stages of development, with its status listed as pending clinical trial initiation.